IGPA Strategic Interest Statement for the TTIP negotiations

The IGPA strongly supports trade negotiations between the European Union and the United States aimed to establish a Transatlantic Trade and Investment Partnership. The IGPA is confident that strengthening transatlantic trade relations will lead to significant job creation and promotion of economic growth.

The generic and biosimilar medicines industries are among the most valuable assets to both EU and US economies; and will therefore, play a pivotal role in contributing to the achievement of such paramount objectives.

The IGPA is convinced that regulatory cooperation between EU and US will lead to the reduction of costs linked to red tape and the removal of administrative burdens, increasing the regulatory convergence between the two sides of the Atlantic.

In this regard, the IGPA considers it fundamental that the two trade partners maintain a high level of ambition in the course of trade negotiations, and is aware that positive results will only be achieved if the highest level of engagement is deployed at all political and technical levels.

The IGPA, through the EGA and the GPhA, is dedicated to the successful development of the EU-US negotiations for a Transatlantic Trade and Investment Partnership, which will contribute to generate new opportunities for the EU-US generic and biosimilar medicines industries in the global context.